An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain.
Phase of Trial: Phase I/II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Samarium 153 lexidronam (Primary) ; Pamidronic acid; Zoledronic acid
- Indications Bone metastases; Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 Planned End Date changed from 1 May 2016 to 1 May 2018.
- 28 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.